drugset / Trial / NCT00033332

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00033332 ↗

RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide in treating patients who have multiple myeloma.

Timeline

Start
2002-04
Primary completion
2006-03
Completion
2006-06

Outcome

Met primary endpoint

paper The response rate with thalidomide plus dexamethasone was significantly higher than with dexamethasone alone (63% v 41%, respectively; P = .0017). PMID 16365178 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg Oral
Subject Thalidomide Other / unclassified 200 mg Oral
Background Pamidronate Small molecule — Intravenous
Background Zoledronic acid Other / unclassified — Intravenous

Indications